Not yet recruiting
Multi-center Study of Three-Dimensional Transesophageal Echocardiography in Patients With Secondary Mitral Regurgitation
NCT07918937· First Hospital of China Medical University· Source
Contact: Juefei Wu (principal investigator)
Recruiting
Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07933471· Phase 2· Beijing Tsinghua Chang Gung Hospital· Source
Contact: Hao Liu
Not yet recruiting
Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
NCT07565415· Phase 2· Nanfang Hospital, Southern Medical University· Source
Contact: Guosheng Yuan
Active, not recruiting
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
NCT07684898· Phase 3· Hangzhou Gensciences Biopharmaceutical Co., Ltd.· Source
Recruiting
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
NCT07547553· Phase 1/2· Huahui Health· Source
Contact: Xiyu Zhang PM
Not yet recruiting
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
NCT07537777· Phase 2· Nanfang Hospital, Southern Medical University· Source
Contact: Li Qi
Active, not recruiting
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
NCT07663903· Phase 3· Hangzhou Gensciences Biopharmaceutical Co., Ltd.· Source
Not yet recruiting
Butylphthalide for Brain Edema After Endovascular Treatment
NCT07528456· Phase 4· Nanfang Hospital, Southern Medical University· Source
Contact: Suyue Pan
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341· Phase 4· Eli Lilly and Company· Source
Contact: RU FENG (principal investigator)
Recruiting
Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis
NCT07360808· Cytori Therapeutics· Source
Contact: NanFang Hospital of Southern Medical University
Recruiting
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
NCT07327788· Phase 2· Nanfang Hospital, Southern Medical University· Source
Contact: Mengya Zang
Recruiting
Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
NCT07436845· Nanfang Hospital, Southern Medical University· Source
Contact: Yuan Guosheng
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Not yet recruiting
PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy
NCT07174375· Phase 2/3· Nanfang Hospital, Southern Medical University· Source
Contact: Kaibin Huang, Ph.D.
Active, not recruiting
Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC
NCT07703228· Phase 2· Nanfang Hospital, Southern Medical University· Source
Recruiting
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013· Phase 1/2· Eli Lilly and Company· Source
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· Phase 3· Pfizer· Source
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
NCT06824168· Phase 2· Daiichi Sankyo· Source
Active, not recruiting
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
NCT06843408· Phase 1/2· Incyte Corporation· Source
Recruiting
SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
NCT07051603· Phase 1· Shenzhen Salubris Pharmaceuticals Co., Ltd.· Source
Contact: Chongyuan Xu, Ph.D
Recruiting
Clinical Value of Intestinal Ultrasound in Predicting Clinical Relapse in Crohn's Disease Patients in Deep Remission: a Multicenter Prospective Observational Study
NCT07539727· Nanfang Hospital, Southern Medical University· Source
Contact: Xinmei Zhao Applicant
Enrolling by invitation
Non-invasive Methods for Predicting Decompensation of Chronic Liver Disease
NCT06741904· Nanfang Hospital, Southern Medical University· Source
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941· Phase 1/2· BeOne Medicines· Source
Contact: Study Director
Recruiting
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06378138· Phase 2/3· Beijing InnoCare Pharma Tech Co., Ltd.· Source
Contact: Xutao Guo
Recruiting
Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
NCT06298968· Phase 2· Nanfang Hospital, Southern Medical University· Source
Contact: Mengya Zang
Recruiting
Modified Intermittent Eating on Weight Loss (INTEREST-3 Trial)
NCT06302803· Nanfang Hospital, Southern Medical University· Source
Contact: Huijie Zhang, MD,PhD
Recruiting
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
NCT06319456· Phase 3· Ascentage Pharma Group Inc.· Source
Contact: Xutao Guo, M.D., Ph.D.
Recruiting
Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT06118788· Phase 1/2· Guangzhou Bio-gene Technology Co., Ltd· Source
Contact: Yu Zhang, MD
Recruiting
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
NCT06035250· Chinese Academy of Sciences· Source
Contact: Guoxin Li
Not yet recruiting
Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer
NCT05730595· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Haijun Deng, Dr.
Recruiting
Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy
NCT05845372· Nanfang Hospital, Southern Medical University· Source
Contact: Suyue Pan
Recruiting
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
NCT05722275· Chinese Academy of Sciences· Source
Contact: Guoxin Li
Active, not recruiting
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565· Phase 2/3· Biogen· Source
Active, not recruiting
Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0)
NCT05511792· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source
Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
NCT05352919· Phase 3· Biogen· Source
Recruiting
Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis
NCT05644314· Nanfang Hospital, Southern Medical University· Source
Contact: Zhong Ji, PHD
Active, not recruiting
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05180734· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Recruiting
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT05147467· Phase 2· Ascentage Pharma Group Inc.· Source
Contact: Ru Feng
Active, not recruiting
A Study of LP-128 Capsules in Healthy Subjects
NCT05130567· Phase 1· Guangzhou Lupeng Pharmaceutical Company LTD.· Source
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236· Phase 3· Pfizer· Source
Active, not recruiting
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· Phase 3· Inventiva Pharma· Source
Active, not recruiting
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567· Phase 3· Biogen· Source
Active, not recruiting
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
NCT04944043· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Active, not recruiting
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622· Phase 3· Pfizer· Source
Active, not recruiting
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT04717414· Phase 3· Celgene· Source
Active, not recruiting
Intracorporeal Anastomosis Versus Extracorporeal Anastomosis for Left Colon Cancer
NCT04201717· Jilin University· Source
Active, not recruiting
Atrasentan in Patients With IgA Nephropathy
NCT04573478· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT04606433· Phase 1· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Recruiting
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
NCT04494503· Phase 1/2· Ascentage Pharma Group Inc.· Source
Contact: Chongyuan Xu Professor
Active, not recruiting
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
NCT04285086· Phase 3· PharmaEssentia· Source
Showing 50 of 53.